United States Biotechnology & Medical Research

ImageneBio Inc (IMA)

Track

Track

ImageneBio Inc. experienced two sell transactions totaling $17,334 by Principal Accounting Officer Robert B. Lally during July 2026. These activities occurred following a 30% earnings report beat in August. The stock price has declined 12.2% over the past quarter, currently trading near its 52-week low.
Ticker: IMA Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for ImageneBio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Lally Robert B Principal Accounting Officer Officer
Transaction date
Sale
Price
482.80
Quantity 2,918 -19.9%
Value US$2,422,489
Lally Robert B Principal Accounting Officer Officer
Transaction date
Sale
Price
108.75
Quantity 52,554 +23.6%
Value US$561,819
3.9
SLATTERY JOSEPH P Non-Executive Director
Transaction date
Purchase
Price
91.83
Quantity 69,792 -14.9%
Value US$4,571,167
3.3
Zhang Xiaoyan Michelle Chief Scientific Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 964 -2.1%
Value US$11,568
3.3
Zhang Xiaoyan Michelle Chief Scientific Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 36 -0.1%
Value US$432
1.5
FORMELA JEAN FRANCOIS Non-Executive Director
Transaction date
Sale
Price
14.00
Quantity 5,959 -0.5%
Value US$83,426
1.5
FORMELA JEAN FRANCOIS Non-Executive Director
Transaction date
Sale
Price
14.64
Quantity 8,330 -0.7%
Value US$121,951
3.3
Zhang Xiaoyan Michelle Chief Scientific Officer Officer
Transaction date
Sale
Price
14.76
Quantity 1,000 -2.2%
Value US$14,760
1.5
FORMELA JEAN FRANCOIS Non-Executive Director
Transaction date
Sale
Price
15.03
Quantity 11,989 -0.9%
Value US$180,195
1.5
FORMELA JEAN FRANCOIS Non-Executive Director
Transaction date
Purchase
Price
16.00
Quantity 125,000 +16.7%
Value US$2,000,000
2.6
ORBIMED ADVISORS LLC Non-Executive Director
Transaction date
Purchase
Price
16.00
Quantity 48,400 +70.2%
Value US$774,400
2.6
ORBIMED ADVISORS LLC Non-Executive Director
Transaction date
Purchase
Price
16.00
Quantity 375,000 +20.6%
Value US$6,000,000
3.1
Bonita David P Non-Executive Director
Transaction date
Purchase
Price
16.00
Quantity 48,400 +70.2%
Value US$774,400
3.1
Bonita David P Non-Executive Director
Transaction date
Purchase
Price
16.00
Quantity 375,000 +20.6%
Value US$6,000,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-20 2026-07-17 S Sale
Lally Robert B

Principal Accounting Officer

Officer
2,918 -19.9%
482.80
US$2,422,489 		2,918 -19.9% 482.80 US$2,422,489
2026-07-20 2026-07-16 S Sale
Lally Robert B

Principal Accounting Officer

Officer
52,554 +23.6%
108.75
US$561,819 		52,554 +23.6% 108.75 US$561,819
2025-12-29 2025-12-24 B Purchase
3.9
SLATTERY JOSEPH P
Non-Executive Director
69,792 -14.9%
91.83
US$4,571,167 		69,792 -14.9% 91.83 US$4,571,167
2022-01-12 2022-01-11 PlS Planned sale
3.3
Zhang Xiaoyan Michelle

Chief Scientific Officer

Officer
964 -2.1%
12.00
US$11,568 		964 -2.1% 12.00 US$11,568
2022-01-12 2022-01-10 PlS Planned sale
3.3
Zhang Xiaoyan Michelle

Chief Scientific Officer

Officer
36 -0.1%
12.00
US$432 		36 -0.1% 12.00 US$432
2021-12-14 2021-12-14 S Sale
1.5
FORMELA JEAN FRANCOIS
Non-Executive Director
5,959 -0.5%
14.00
US$83,426 		5,959 -0.5% 14.00 US$83,426
2021-12-14 2021-12-14 S Sale
2.0
Atlas Venture Fund XI, L.P.
Large shareholder
5,959 -0.5%
14.00
US$83,426 		5,959 -0.5% 14.00 US$83,426
2021-12-14 2021-12-13 S Sale
1.5
FORMELA JEAN FRANCOIS
Non-Executive Director
8,330 -0.7%
14.64
US$121,951 		8,330 -0.7% 14.64 US$121,951
2021-12-14 2021-12-13 S Sale
2.0
Atlas Venture Fund XI, L.P.
Large shareholder
8,330 -0.7%
14.64
US$121,951 		8,330 -0.7% 14.64 US$121,951
2021-12-14 2021-12-10 S Sale
3.3
Zhang Xiaoyan Michelle

Chief Scientific Officer

Officer
1,000 -2.2%
14.76
US$14,760 		1,000 -2.2% 14.76 US$14,760
2021-12-14 2021-12-10 S Sale
1.5
FORMELA JEAN FRANCOIS
Non-Executive Director
11,989 -0.9%
15.03
US$180,195 		11,989 -0.9% 15.03 US$180,195
2021-12-14 2021-12-10 S Sale
2.0
Atlas Venture Fund XI, L.P.
Large shareholder
11,989 -0.9%
15.03
US$180,195 		11,989 -0.9% 15.03 US$180,195
2021-12-14 2021-03-30 B Purchase
1.5
FORMELA JEAN FRANCOIS
Non-Executive Director
125,000 +16.7%
16.00
US$2,000,000 		125,000 +16.7% 16.00 US$2,000,000
2021-12-14 2021-03-30 B Purchase
2.0
Atlas Venture Fund XI, L.P.
Large shareholder
125,000 +16.7%
16.00
US$2,000,000 		125,000 +16.7% 16.00 US$2,000,000
2021-04-01 2021-03-30 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
48,400 +70.2%
16.00
US$774,400 		48,400 +70.2% 16.00 US$774,400
2021-04-01 2021-03-30 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
375,000 +20.6%
16.00
US$6,000,000 		375,000 +20.6% 16.00 US$6,000,000
2021-04-01 2021-03-30 B Purchase
3.1
Bonita David P
Non-Executive Director
48,400 +70.2%
16.00
US$774,400 		48,400 +70.2% 16.00 US$774,400
2021-04-01 2021-03-30 B Purchase
3.1
Bonita David P
Non-Executive Director
375,000 +20.6%
16.00
US$6,000,000 		375,000 +20.6% 16.00 US$6,000,000
Explore more

More insider trading research around ImageneBio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America